In Asia, a Japanese randomized phase II trial (Trigger: UMIN000016920) is ongoing to evaluate pre-operative use of trastuzumab as a strategy of peri-operative therapy for HER2-positive, extensively LN-positive, resectable GC (Table 2). The gene discussed is ERBB2; the disease is gastric cancer.